SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptor (ERR) family, activating all three subtypes, ERRα, ERRβ and ERRγ, with the highest binding affinity reported at ERRα. First characterised by researchers at Saint Louis University, from which the compound derives its “SLU” designation, slu pp 332 activates a nuclear transcriptional programme normally associated with endurance exercise adaptation, without engaging the classical estrogen receptors ERα or ERβ despite the structural naming similarity. Within laboratory research, SLU-PP-332 is used to study mitochondrial biogenesis, oxidative skeletal muscle fibre programming and cellular metabolic reprogramming through a receptor-mediated mechanism distinct from conventional hormonal or growth-factor signalling pathways.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small-molecule compound rather than a peptide, despite frequently being catalogued and discussed alongside peptide research compounds in the research chemical literature and supplier listings. It was developed and characterised in the laboratory of Thomas P. Burris at Saint Louis University, with published pharmacological characterisation appearing in the peer-reviewed literature beginning in 2023. The compound was designed specifically as a research tool capable of simultaneously activating all three estrogen-related receptor subtypes, allowing researchers to study the combined physiological consequences of pan-ERR activation in a single experimental system.
Estrogen-related receptors are a subfamily of orphan nuclear receptors, identified in 1988 based on their sequence homology to the classical estrogen receptors, from which they derive their name. Despite this structural relationship and naming convention, ERRs do not bind estrogen or estradiol. They are constitutively active transcription factors, meaning they adopt a transcriptionally active conformation independent of ligand binding, and their activity is instead regulated by cellular energy status and by interaction with transcriptional coactivators, principally PGC-1α. This distinguishes ERRs fundamentally from classical estrogen receptors ERα and ERβ, which require estrogen binding for activation and which mediate reproductive and hormonal signalling rather than metabolic gene regulation.
Published receptor-binding characterisation has reported that SLU-PP-332 activates ERRα with an EC50 of approximately 98 nM, ERRβ at approximately 230 nM, and ERRγ at approximately 430 nM, establishing it as an approximately four-fold more potent agonist at ERRα relative to ERRγ, with ERRβ potency intermediate between the two. This graded selectivity profile is relevant to researchers interpreting SLU-PP-332 experimental findings, since ERRα is understood to be the dominant isoform driving mitochondrial and oxidative metabolic gene programmes in skeletal muscle, heart and brown adipose tissue, the tissues in which SLU-PP-332 research has been most extensively concentrated.
SLU-PP-332’s distinction from traditional metabolic modulators lies in its receptor-level mechanism. Unlike compounds that act as exercise mimetics through AMPK activation, PPAR agonism, or other established metabolic signalling routes, SLU-PP-332 works by directly activating the ERR family of transcription factors that sit downstream of, and interact closely with, the exercise-responsive coactivator PGC-1α. This positions SLU-PP-332 mechanistically closer to the terminal transcriptional machinery governing mitochondrial and oxidative gene expression, rather than acting on more upstream metabolic sensing pathways, a distinction relevant to researchers designing comparative studies against other classes of metabolic research compounds.
Mechanism of Action
The central mechanism of SLU-PP-332 is direct co-activation of ERRα, ERRβ and ERRγ, which in turn drives transcription of gene networks controlled by these nuclear receptors in partnership with the coactivator PGC-1α. ERRα has been established in the published literature as an essential effector of PGC-1α-driven mitochondrial biogenesis; research using ERRα-null cells has demonstrated that PGC-1α loses much of its capacity to induce mitochondrial gene expression and mitochondrial DNA content in the absence of functional ERRα, indicating that ERRα is not merely one of several redundant routes for PGC-1α signalling but a required intermediate for a substantial portion of its downstream transcriptional programme.
Downstream of ERR activation, published research has documented upregulation of genes governing fatty acid oxidation, the tricarboxylic acid cycle, oxidative phosphorylation, and mitochondrial biogenesis itself. ERRα has specifically been shown to direct PPARα signalling in cardiac and skeletal muscle, coactivating expression of genes involved in fatty acid uptake and mitochondrial and peroxisomal fatty acid oxidation, indicating that ERRα-mediated transcription operates in coordination with, and partially channels through, the PPARα signalling axis rather than acting as a fully independent transcriptional programme. ERRα-dependent transcription has also been linked to expression of antioxidant protection genes, with research in ERRα-null cells reporting that PGC-1α’s induction of mitochondrial oxidative stress protection genes is specifically dependent on ERRα, and that basal levels of the antioxidant regulator nuclear respiratory factor 2 (NRF-2) are reduced in the absence of ERRα, connecting SLU-PP-332’s mechanism to cellular oxidative stress management alongside its more extensively documented bioenergetic effects.
Mitochondrial mass expansion has been documented as a functional consequence of this transcriptional programme, with treatment increasing expression of both mitochondrial biogenesis genes and oxidative phosphorylation genes, leading to enhanced mitochondrial function, oxygen consumption and ATP production in skeletal muscle cell line studies. Fatty acid oxidation gene upregulation has been reported alongside these mitochondrial effects, consistent with ERR-driven transcription of the enzymatic machinery required for increased reliance on fat oxidation as a metabolic fuel source, a shift characteristic of trained, endurance-adapted skeletal muscle tissue.
Oxidative type I muscle fibre programme induction represents a further well-documented downstream effect. Research in mouse skeletal muscle has reported that SLU-PP-332 treatment activates an acute transcriptional signature resembling that induced by aerobic exercise and increases the proportion of oxidative muscle fibre types, effects that have been demonstrated to depend on functional ERRα signalling, since the effect is lost in ERRα-deficient animal models. This receptor-dependency finding is mechanistically important, confirming that SLU-PP-332’s muscle fibre-programming and exercise-signature-inducing effects operate specifically through the ERR pathway rather than through an off-target mechanism. Cellular energy expenditure modulation has been documented as a systemic consequence of these combined transcriptional effects, consistent with SLU-PP-332’s characterisation in the literature as a chemical exercise mimetic, a compound capable of reproducing selected cellular adaptations of aerobic exercise through pharmacological receptor activation rather than through mechanical physical activity.
What the Research Shows
The foundational pharmacological characterisation of SLU-PP-332 was published by Billon and colleagues, who reported that the compound binds and activates ERRα, ERRβ and ERRγ, with a single intraperitoneal dose sufficient to induce an acute aerobic exercise transcriptional signature in mouse skeletal muscle within hours of administration. This study demonstrated increased proportion of oxidative type IIa muscle fibres and enhanced treadmill exercise capacity in treated mice, with these effects shown to depend on functional ERRα signalling through loss-of-effect experiments in ERRα-deficient animals (SLU-PP-332 exercise-mimetic characterisation study).
A related study from the same research group examined SLU-PP-332 in the context of metabolic dysfunction, reporting effects on markers of metabolic syndrome in preclinical rodent models, extending the compound’s characterised research profile beyond acute exercise-signature induction to broader metabolic regulation relevant to lipid accumulation resistance and systemic metabolic rate research (SLU-PP-332 metabolic syndrome study).
Underlying mechanistic research establishing ERRα’s essential role in mitochondrial biogenesis and antioxidant gene regulation, foundational to interpreting SLU-PP-332’s downstream effects, demonstrated using ERRα-null cell models that PGC-1α-driven induction of both mitochondrial oxidative stress protection genes and the antioxidant regulator NRF-2 is specifically dependent on functional ERRα, establishing the receptor as a required node connecting PGC-1α coactivator signalling to both bioenergetic and antioxidant transcriptional programmes (ERRα antioxidant and mitochondrial function study).
Rodent endurance testing models featured centrally in the foundational SLU-PP-332 characterisation work, using treadmill exhaustion protocols to quantify exercise capacity changes following compound administration, with reported improvements in running endurance in treated animals relative to untreated controls, interpreted as evidence that pharmacological pan-ERR activation can reproduce a meaningful component of the endurance-training adaptive phenotype without requiring physical training itself. Mitochondrial respiration profiles have been examined using skeletal muscle cell line studies, reporting elevated cellular respiration rates and metabolic efficiency following SLU-PP-332 exposure without evidence of cytotoxicity in the concentration ranges studied, findings relevant to researchers designing cell-culture bioenergetics protocols using this compound.
Research Applications
Within laboratory settings, SLU-PP-332 research peptide preparations, despite the compound’s small-molecule rather than peptide chemical classification, are used across several established metabolic research contexts. Skeletal muscle cell bioenergetics assays represent a core application, in which researchers use techniques such as extracellular flux analysis or high-resolution respirometry to characterise oxygen consumption, ATP production and mitochondrial respiratory capacity in cultured skeletal muscle cell lines following SLU-PP-332 exposure, building directly on the cellular respiration findings reported in the foundational literature.
Mitochondrial biogenesis expression profiling constitutes a further major research application, using quantitative PCR or Western blot techniques to characterise expression changes in genes governing mitochondrial DNA replication, oxidative phosphorylation complex assembly and overall mitochondrial mass following compound exposure, providing a molecular readout that complements functional bioenergetics assay data. Lipid flux studies are used to examine fatty acid oxidation capacity and lipid accumulation resistance in cell culture or animal-model systems, reflecting SLU-PP-332’s documented effects on fatty acid oxidation gene expression and its proposed relevance to metabolic dysfunction research contexts.
Metabolic exercise-mimetic research setups represent a particularly active area of investigation, in which researchers compare SLU-PP-332 treatment against actual physical exercise protocols in animal models, examining the degree of transcriptional and functional overlap between pharmacological ERR activation and genuine endurance training adaptation, a comparative research design directly informed by the compound’s characterisation as a chemical exercise mimetic in the foundational literature. When selecting a certified SLU-PP-332 research peptide for cellular bioenergetics or mitochondrial biogenesis protocols, researchers should confirm the compound’s exact chemical structure and purity documentation supplied, since researchers should be aware that, despite common product naming conventions describing SLU-PP-332 as a peptide, it is chemically a synthetic small molecule, a distinction relevant to selecting appropriate analytical verification and handling protocols.
Comparative pharmacology work has also examined SLU-PP-332 alongside other ERR-pathway-related compounds and alongside established exercise-mimetic research tools acting through distinct mechanisms, such as AMPK-activating compounds, providing researchers with a broader comparative framework for studying convergent versus distinct routes to pharmacologically induced mitochondrial and oxidative metabolic adaptation.
Purity, Analytical Verification, Storage and Handling
Research-grade SLU-PP-332 should be accompanied by a certificate of analysis confirming purity by HPLC, typically at or above 98 percent, together with mass spectrometry verification confirming the correct molecular structure and identity of this synthetic small-molecule compound. Because SLU-PP-332 is chemically distinct from peptide research compounds despite common informal naming conventions, analytical verification should specifically confirm small-molecule identity and purity via methods appropriate to this compound class, rather than assuming that peptide-specific analytical protocols transfer directly. When evaluating high-purityslu pp 332 for laboratory metabolic assays, UK research facilities must ensure each lot is verified using this documentation rather than relying on a generic product listing.
SLU-PP-332 should be stored at -20°C, protected from light and moisture, in order to preserve chemical stability prior to use in experimental protocols. Solubility characteristics differ from those of many peptide research compounds; SLU-PP-332 preparation for cell culture or animal-model use typically requires solubilisation in appropriate organic solvents, such as DMSO, prior to dilution into aqueous buffer systems, and researchers should confirm the maximum stock solution concentration and appropriate dilution protocol with reference to published experimental methodology rather than assuming direct aqueous solubility. Stability protocols for prepared stock solutions should account for potential solvent-dependent degradation, and researchers should follow supplier-specific guidance regarding stock solution storage duration and appropriate use of freeze-thaw cycling limits for solvent-based preparations.
Frequently Asked Questions
Is SLU-PP-332 a peptide, despite being commonly listed alongside peptide research compounds?
No. SLU-PP-332 is chemically a synthetic small molecule, not a peptide, despite frequently being catalogued alongside peptide research products in supplier listings and informal research literature. Researchers should account for this distinction when selecting appropriate analytical verification and solubility handling protocols.
Why is SLU-PP-332 described as an ERR pan-agonist rather than being selective for one receptor subtype?
Published receptor-binding data indicates that SLU-PP-332 activates all three estrogen-related receptor subtypes, ERRα, ERRβ and ERRγ, though with graded potency, being most potent at ERRα. This pan-agonist profile was a deliberate design goal, allowing researchers to study the combined effect of activating all three ERR subtypes simultaneously.
Does SLU-PP-332 have any activity at the classical estrogen receptors?
No. Despite the structural naming similarity between estrogen-related receptors and classical estrogen receptors, SLU-PP-332 does not engage ERα or ERβ. Estrogen-related receptors are constitutively active transcription factors regulated by cellular energy status and coactivator interaction, not by estrogen binding.
How should research-grade SLU-PP-332 be verified before use in an assay?
Researchers should request a batch-specific certificate of analysis confirming HPLC purity of 98 percent or higher and mass spectrometry confirmation of the correct small-molecule structure, along with confirmation of appropriate solvent solubility data, since this compound’s chemical class differs from peptide research products and requires correspondingly appropriate verification methods.
SLU-PP-332, as supplied by Peptides Lab UK and comparable UK research suppliers, is intended strictly for in-vitro and animal-model laboratory research. It is not licensed or intended for human or veterinary use, and nothing in this article should be interpreted as guidance for personal administration